PharmaCyte Long Term Debt To Capitalization from 2010 to 2024
| PMCB Stock | USD 1.75 0.04 2.34% |
Long Term Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.008111 | Current Value 0.008517 | Quarterly Volatility 0.48678594 |
Check PharmaCyte Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PharmaCyte Biotech's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Other Operating Expenses of 5.6 M or EBITDA of 350.4 K, as well as many indicators such as Price To Sales Ratio of 3.3 K, Dividend Yield of 0.0078 or PTB Ratio of 0.54. PharmaCyte financial statements analysis is a perfect complement when working with PharmaCyte Biotech Valuation or Volatility modules.
PharmaCyte | Long Term Debt To Capitalization |
Latest PharmaCyte Biotech's Long Term Debt To Capitalization Growth Pattern
Below is the plot of the Long Term Debt To Capitalization of PharmaCyte Biotech over the last few years. It is PharmaCyte Biotech's Long Term Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PharmaCyte Biotech's overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt To Capitalization | 10 Years Trend |
|
Long Term Debt To Capitalization |
| Timeline |
PharmaCyte Long Term Debt To Capitalization Regression Statistics
| Arithmetic Mean | 0.13 | |
| Geometric Mean | 0.01 | |
| Coefficient Of Variation | 361.65 | |
| Mean Deviation | 0.23 | |
| Median | 0.01 | |
| Standard Deviation | 0.49 | |
| Sample Variance | 0.24 | |
| Range | 1.8861 | |
| R-Value | (0.43) | |
| Mean Square Error | 0.21 | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | (0.05) | |
| Total Sum of Squares | 3.32 |
PharmaCyte Long Term Debt To Capitalization History
About PharmaCyte Biotech Financial Statements
PharmaCyte Biotech stakeholders use historical fundamental indicators, such as PharmaCyte Biotech's Long Term Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although PharmaCyte Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in PharmaCyte Biotech's assets and liabilities are reflected in the revenues and expenses on PharmaCyte Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PharmaCyte Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt To Capitalization | 0.01 | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out the analysis of PharmaCyte Biotech Correlation against competitors. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.64 | Return On Assets (0.05) | Return On Equity 0.4788 |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.